Open Label Placebo in the Treatment of Low Back Pain
CompletedPhase 2NCT02022124
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Patients will be randomized to receive open-label (honestly described placebo) immediately at baseline or be eligible to receive the open-label treatment three weeks after the baseline measurements. Therefore all patients will be eligible to receive open-label placebo treatment for their chronic low back pain during the course of the study.
Study details
- Official title
- Open Label Placebo in the Treatment of Low Back Pain
- Conditions
- Interventions
- Drug: Microcrystalline cellulose (open-label inert substance)
- Sponsor
- Hospital de Egas Moniz
- Start date
- 2013-11
- Primary completion
- 2015-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Portugal
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female * 18 years or older * Low back pain complaints for a min. of 3 months Exclusion Criteria: * use of strong opioid analgesic and/or anticonvulsant medication; * specific causes of back pain namely cancer, fractures and infections; * complicated back problems (e.g. prior back surgery); * conditions making treatment difficult (e.g. paralysis, psychoses); * conditions that might confound treatment effects or interpretation of results (e.g. severe fibromyalgia, rheumatoid arthritis); * concurrent care from other providers; * conditions that affect safety of patient (e.g. pregnancy); * concurrent medical legal issues.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02022124